Aspects of atherosclerosis and metabolic syndrome in lupus erythematosus;Aspectos da aterosclerose e da síndrome metabólica no lúpus eritematoso sistêmico

Acta Reumatologica Portuguesa

Volumn 35, Issue 3, 2010, Pages 294-300

  Nascimento, Iana Sousa ^a   Quaio, Caio Robledo D'Angioli Costa ^a   Sinicato, Nailú Angélica ^b   Appenzeller, Simone ^b   De Carvalho, Jozélio Freire ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cardiovascular disease; Dyslipidemia; Metabolic dyndrome; Systemic lupus erythematosus

Indexed keywords

EID: 78650453648     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:32-38.
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-415.
3. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-225.
4. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000;9:166-169.
5. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-519.
6. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology (Oxford) 2000;39:353-359.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
8. Negrón A, Molina M, Mayor A, Rodríguez V, Vilá L. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 2008;17:348-354.
9. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008;14:74-77.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy R P, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979. [Erratum, N Engl J Med 1997;337:356].
11. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89: 2462-2478.
12. Napoli C, D'Armiento F P, Mancini F P, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997;100:2680-2690.
13. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
14. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
15. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
16. Wysocki J, Skoczynski S, Strozik A, Hochul B, Zygula M. Metabolic or immunometabolic syndrome? Wiad Lek 2005;58:124-127.
17. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:792-800.
18. Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 2001;119:122-127.
19. Galtier-Dereure F, Biron C, Vies M, Bourgeois V, Schved J F, Bringer J. Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? Lupus1998;7:469-474.
20. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-3163.
21. Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27.
22. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-795.
23. Reichlin M, Fesmire J, Quintero-Del-Rio AI, WolfsonReichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46:2957-2963.
24. de Carvalho J F, Borba E F, Viana VS, Bueno C, Leon E P, Bonfa E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004;50:3610-3615.
25. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for sub-clinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-1077.
26. Ross R. Atherosclerosis--an inflammatory disease. Engl J Med 1999;340:115-126.
27. Borba E F, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-539.
28. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-863.
29. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999;26:2137-2143.
30. de Carvalho J F, Bonfá E, Borba E F. Systemic lupus erythematosus and "lúpus dyslipoproteinemia". Autoimmun Rev 2008;7:246-250.
31. Borba E F, Carvalho J F, Bonfá E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006;13:203-208.
32. de Carvalho J F, Borba E F, Viana VS, Bueno C, Leon E P, Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004;50:3610-3615.
33. WHO consultations: Definition, diagnosis and classification of diabetes mellitus and its complications. WHO/NCD/NCS/992:31-33.
34. Lopes H F. Síndrome Metabólica: aspectos históricos, prevalência, e morbidade e mortalidade. Rev Soc Cardiol 2004; 4:539-543.
35. Alberti RG. Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
36. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-223.
37. Harano Y, Ohgaku S, Hidaka H, et al. Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 1977;45: 1124-1127.
38. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-677.
39. Caumo A, Vicini P, Cobelli C. Is the minimal model too minimal? Diabetologia 1996;39:997-1000.
40. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-965.
41. Matthews DR, Hosker J P, Rudenski AS, Naylor BA, Treacher D F, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
42. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285:2486-2497.
43. World Health Organisation, Western Pacific Region, The Asia-Pacific Perspective. Redefining Obesity and its Treatment, WHO/IASO/IOTF (2000).
44. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Bmj 1995;311:158-161.
45. Alberti KGMM, Eckel RH, Scott M, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120; 1640-1645.
46. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005;181:101-108.
47. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005;181:143-148.
48. Rosenbaum P, Gimeno SG, Sanudo A, Franco LJ, Ferreira SR. Analysis of criteria for metabolic syndrome in a population-based study of Japanese-Brazilians. Diabetes Obes Metab 2005;7:352-359.
49. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. The metabolic syndrome: a concept hard to define. Arch Med Res 2005;36:223-231.
50. Rodriguez A, Muller DC, Engelhardt M, Andres R. Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. Metabolism 2005;54:542-547.
51. Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005;28:27-34.
52. Bo S, Gentile L, Ciccone G, et al. The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 2005;21:515-524.
53. Chung C P, Avalos I, Oeser A, et al High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2006; 66: 208-214.
54. Azevedo GD, Gadelha RG, Vilar MJ. Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA. Ann Rheum Dis 2007;66:1542.
55. Sabio J, Zamora-Pasadas M, Jiménez-JáimezMEZ J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849-859.
56. Pereira RM, de Carvalho J F, Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8:415-419.
57. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythe-matosus: a longitudinal data analysis. Am J Med 1994;96:254-259.
58. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719.
59. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-933.